Indications and clinical use:

COSENTYX® is indicated for the treatment of: 

• Moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy. 

• Moderate to severe plaque psoriasis in pediatric patients 6 years and older who are candidates for systemic therapy or phototherapy. 

• Active psoriatic arthritis in adult patients when the response to previous disease-modifying anti-rheumatic drug (DMARD) therapy has been inadequate. COSENTYX® can be used alone or in combination with methotrexate. 

• Active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy. 

• Active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence in adults who have responded inadequately, or are intolerant to nonsteroidal anti-inflammatory drugs (NSAIDs). 

• Juvenile idiopathic arthritis categories: 

  • Active enthesitis-related arthritis in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy.


  • Active juvenile psoriatic arthritis in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy.

• Moderate to severe hidradenitis suppurativa (acne inversa) in adult patients who have responded inadequately to conventional systemic hidradenitis suppurativa therapy.

Geriatric patients ≥65 years of age: although limited in patient numbers, no differences in safety or efficacy were observed between older and younger patients.

Pediatrics <18 years of age: safety and effectiveness in pediatric patients with moderate to severe plaque psoriasis below the age of 6 years have not been established. Safety and effectiveness in pediatric patients below the age of 18 years in other indications have not yet been established. Safety and effectiveness in pediatric patients with the JIA categories of ERA and JPsA below the age of 6 years have not been established.

Relevant warnings and precautions:

• Infections 

• Inflammatory bowel disease 

• Hypersensitivity reactions 

• Latex-sensitive patients

• Eczematous eruptions 

• Immunizations 

• Pregnant and nursing women

For more information:

Consult the Product Monograph at www.novartis.ca/CosentyxMonograph for important information relating to adverse reactions, drug interactions and dosing information which has not been discussed in this piece. The Product Monograph is also available by calling 1-800-363-8883.